Fatal pulmonary embolism in patients on antipsychotics: case series, systematic review and meta-analysis

Asian J Psychiatr. 2022 Jul:73:103105. doi: 10.1016/j.ajp.2022.103105. Epub 2022 Apr 12.

Abstract

Since the 1950 s, several studies have reported that patients using first generation and/or second-generation antipsychotics had increased risk of venous thromboembolism events. These events include deep vein thrombosis and/or pulmonary embolism (PE). However, data about fatal PE in patients on antipsychotics (APs) remain scarce. Thus, the current study aimed to investigate sociodemographic, clinical and pharmacological characteristics related to psychiatric patients on APs and who died from a fatal PE. We reported a case-series, then conducted a literature review of relevant studies and performed a meta-analysis of studies with usable data. The main outcome of the study suggested a significantly high risk of fatal PE in patients using APs compared to nonusers (Odds Ratio=6.68, with 95% confidence interval 1.43-31.11). Clozapine was the most incriminated drug. Low potency first generation APs were the second most exhibited medication. Studies about the topic remain scarce with a high heterogeneity and a high probability of bias. Further studies are needed to ascertain this risk and to establish target preventive measures in this particularly vulnerable population.

Keywords: Antipsychotic Agent; Cause of Death; Psychiatry; Pulmonary Embolism; Thromboembolism.

Publication types

  • Meta-Analysis
  • Review
  • Systematic Review

MeSH terms

  • Antipsychotic Agents* / adverse effects
  • Clozapine*
  • Humans
  • Odds Ratio
  • Pulmonary Embolism* / chemically induced
  • Pulmonary Embolism* / epidemiology
  • Risk Factors
  • Venous Thromboembolism* / chemically induced
  • Venous Thromboembolism* / epidemiology

Substances

  • Antipsychotic Agents
  • Clozapine